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Abstract 
Aim. To report the development of a core set of outcome domains for clinical research 
involving adults with incontinence-associated dermatitis or at risk, independently from any 
geographical location or skin colour. 
 
Background. The management of incontinence-associated dermatitis is important in caring 
for incontinent patients. The lack of comparability of clinical trial outcomes is a major 
challenge in the field of evidence-based incontinence-associated dermatitis prevention and 
treatment. Core outcome sets may therefore be helpful to improve the value of clinical 
incontinence-associated dermatitis research.  
 
Design. Systematic literature review, patient interviews and consensus study using Delphi 
procedure. 
 
Methods. A list of outcome domains was generated through a systematic literature review 
(no date restrictions – April 2016), consultation of an international steering committee and 
three patient interviews . The project team reviewed and refined the outcome domains prior 
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to starting a three-round Delphi procedure conducted between April - September 2017. The 
panellists, including healthcare providers, researchers and industry were invited to rate the 
importance of the outcome domains. 
 
Results. We extracted 1852 outcomes from 244 articles. Experts proposed 56 and patients 32 
outcome domains. After refinement, 57 panellists from 17 countries rated a list of 58 outcome 
domains. The final list of outcome domains includes erythema, erosion, maceration, IAD-
related pain and patient satisfaction. 
 
Conclusion. Erythema, erosion, maceration, incontinence-associated dermatitis -related pain 
and patient satisfaction are the most important outcome domains to be measured in 
incontinence-associated dermatitis trials. Based on this international consensus on what to 
measure, the question of how to measure these domains now requires 
consideration.Registration This project has been registered in the Core Outcome Measures in 
Effectiveness Trials (COMET Initiative) database and is part of the Cochrane Skin Group - 
Core Outcomes Set Initiative (CSG-COUSIN). 
 
Keywords Clinical nursing research, Contact dermatitis, Core outcome set, Dermatology, 
Domains, Incontinence-associated dermatitis, Nursing, Outcome assessment, Outcomes, 
Outcomes research  
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Summary statement 
Why this research is needed? 
 Incontinence-associated dermatitis is a burden for both patients and for their 
caregivers. Adequate prevention and treatment of incontinence-associated dermatitis 
are therefore essential. 
 A wide range of products is available but studies on the efficacy and (cost-) 
effectiveness cannot adequately be compared because of the large variety of outcomes 
used and their related measures. 
 To date, there is no consensus on which outcomes to measure in clinical effectiveness 
trials in the field of incontinence-associated dermatitis.  
 
What are the key findings? 
 Core outcome domains to be reported in incontinence-associated dermatitis clinical 
trials have been identified. 
 Erythema, maceration, erosion, IAD-related pain and patient satisfaction are 
considered as most important to measure. 
How should the findings be used to influence policy/practice/research/education? 
 Researchers should focus on the identified core outcome domains when planning and 
conducting clinical trials in the field of incontinence-associated dermatitis.  
 Research is needed to identify most appropriate ways to measure the core outcome 
domains.  
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INTRODUCTION 
Incontinence-associated dermatitis (IAD) is an irritant contact dermatitis caused by the 
prolonged and repeated exposures of the skin to urine and/or faeces. It is characterized by 
erythema and oedema of the perianal and/or genital skin. In some cases, IAD is accompanied 
by bullae, erosion or secondary cutaneous infection (Gray et al. 2012). Skin surface wetness, 
chemical and physical irritants trigger inflammation and skin damage (Beeckman et al. 2009, 
Mugita et al. 2015). Patients with IAD may experience discomfort because of pain, itching, 
burning or tingling (Van Damme et al. 2015). In addition to these physical complaints, IAD 
has an impact on the psychological and social functioning such as the loss of independence 
(Beeckman et al. 2015, Van Damme et al. 2015). 
 
Background  
Managing IAD is an important challenge for healthcare professionals. Prevention and 
treatment of IAD include skin cleansing and the topical application of leave-on products for 
skin protection and healing (Kottner and Beeckman 2015). A Cochrane review on skin care 
interventions for managing IAD revealed a substantial heterogeneity of reported outcomes 
and instruments in IAD research (Beeckman et al. 2016). The lack of comparability between 
studies about efficacy and (cost-) effectiveness of products and procedures complicates 
standardization of IAD prevention and treatment. To overcome this challenge, the 
development and use of a Core Outcome Set (COS) should improve the situation.  
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A COS is a consensus-derived minimum set of outcomes that should be measured and 
reported in clinical trials of a specific health condition (Williamson et al. 2017). A COS may 
also be suitable for use in other types of research and clinical audits (Williamson et al. 2017). 
It does not limit the researchers to choose additional outcomes and measurements (Schmitt et 
al. 2014). 
 
Different methodological frameworks are available to guide the development of a COS, such 
as the Core Outcome Measures in Effectiveness Trials (COMET) Initiative, the Outcome 
Measures in Rheumatology (OMERACT) group and the Harmonizing Outcomes Measures 
for Eczema (HOME) roadmap endorsed by the Cochrane Skin Group Core Outcomes Set 
Initiative (CSG-COUSIN) (Boers et al. 2014b, Schmitt et al. 2014, Williamson et al. 2017). A 
stepped approach is suggested in all frameworks: first the selection of core outcome domains 
(‘what’ to measure) and second to determine the measurement instruments (‘how’ to 
measure). All frameworks emphasize the importance of involving relevant stakeholders 
throughout the whole process. The involvement of stakeholders increases the number of 
ideas, establishes credibility and ensures relevance that would not have otherwise been 
considered (Boers et al. 2014b). The perspective of patients living with the health condition is 
also considered essential (Williamson et al. 2012b, Young and Bagley 2016).  
To date, there is no consensus on which outcomes to measure in clinical effectiveness trials in 
the field of IAD (Van den Bussche et al. 2017). The use of a COS will contribute to the 
reduction of outcome reporting bias and it will enhance the comparability of study results 
worldwide leading to a stronger evidence-base (Kirkham et al. 2013, Williamson et al. 2012a, 
Williamson et al. 2017). The Core Outcome Set in IAD Research (CONSIDER) project aims 
to develop a COS in the area of IAD.  
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THE STUDY 
Aim 
The aim of this project was to develop a consensus-based set of core outcome domains to be 
applied in clinical research involving adults with IAD or at risk of IAD, independently from 
any geographical location or skin colour. 
 
Design 
The project consists of four phases: preparation (phase 1), development of a core set of 
outcome domains (phase 2), development of a core set of outcome measurements (phase 3) 
and the dissemination and monitoring (phase 4). This article describes phases 1 and 2, using 
the Core Outcome Set-Standards for Reporting (COS-STAR) statement to enhance reporting 
quality (Kirkham et al. 2016). Study methods are described in brief as they have been 
presented in detail previously in the published protocol (Van den Bussche et al. 2017).  
The project team (PT) consisting of four people (KV, DD, JK, DB) designed and coordinated 
the study. An International Steering Committee (ISC) of six experts in the field of 
dermatology, geriatrics, wound care, trials and nursing (HB, MP, SS, SE, LS, AMD) guided 
the development of the COS. Four people (TL, NV, SV, AV) provided methodological 
support during the study conduct. 
 
Data collection 
This research project was performed between April 2016 - September 2017 in two phases: (1) 
the generation of the list of outcomes and (2) a three-round Delphi procedure with panellists. 
An overview of the COS development process is provided in Figure 1. 
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Generation of the list of outcomes 
A list of outcomes was generated based on a systematic literature review (with no date 
restrictions up to April 2016), consultation with the ISC and interviews with three patients 
from April 2016 – June 2016. Patients with a present or past experience of IAD and a good 
cognitive function were recruited via patient associations in Belgium and the Netherlands and 
the geriatric ward of the Ghent University Hospital. Two patients living at home responded 
via e-mail to the call disseminated via the patient associations. One patient diagnosed with 
IAD was considered eligible to participate by the head nurse of the geriatric ward. 
 
A detailed description of the literature review was published previously (Van den Bussche et 
al. 2017). Four electronic databases, Web of Science, PubMed, CINAHL and the Cochrane 
Library were systematically searched for relevant papers dating through April 6, 2016. Two 
reviewers (KV & DD) independently assessed all records obtained, a third reviewer (DB) 
reviewed if necessary. Data extraction of all primary and secondary endpoints was performed 
by one author (KV). If the paper did not explicitly mention the outcomes that they measured, 
then the reviewer inferred these from the given data. 
 
The independent data extraction of 10% of the papers by a second reviewer and subsequent 
inter-rater agreement calculation was challenging, because of the complexity of reporting in 
the original papers. The project team discussed outcomes addressing similar concepts and 
classified these using the OMERACT framework (Boers et al. 2014a). This long list of 
outcomes was presented to the ISC prior to the Delphi study. 
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Delphi procedure 
A list of practitioners and researchers was created by one author (KV) from the included 
studies in the literature review. Other healthcare providers and researchers were added to this 
list using additional searches. A deviation from the protocol was the addition of stakeholders 
from industry and recommended colleagues by participating panellists to increase the size of 
the panel. The ISC members were invited as panellists as well. The final list of potential 
panellists was managed by one member of the project team (KV) and remained blinded to all 
those selected for participation.  
A three-round Delphi was conducted. Panellists were invited by email to participate. The 
online survey was developed and hosted by the CSG-COUSIN. In the first round, the 
panellists were randomly divided into two groups prior to the invitation to participate. Group 
1 rated the importance of the outcome domains on a three-point scale: (1) not important 
enough to be considered in the COS for IAD, (2) important but not critical to be considered in 
the COS for IAD and (3) critical, should be included in the COS for IAD. Group 2 rated the 
importance of the outcome domains on a nine-point scale with descriptors on the ends of the 
spectrum: from (1) not important for inclusion in COS for IAD, to (9) critical, should be 
included in COS for IAD. Both groups were given the opportunity to choose the option ‘I 
can’t rate the importance of the outcome because I don’t know the outcome’, to add feedback 
or rationale per outcome and to add additional outcomes. The outcome domains were sorted 
alphabetically to avoid weighting of outcome domains due to the order. Outcome domains 
rated critical in both groups were included in the second round. In the second round, the nine-
point scale was used for all panellists to rate the importance of the outcome domains. In the 
third and final round, the panellists were asked to approve the remaining outcome domains on 
a three-point scale: (1) Yes, I approve, (2) Yes, I approve but with minor suggestions and (3) 
No, I have major concerns. 
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A variation from the protocol was that only responders were invited to participate in the next 
round. Consensus was defined as at least 70% of all panellists rating the outcome domains as 
‘critical for inclusion in a COS for IAD research’. Descriptive statistics were used to 
summarize the demographic characteristics and the responses of the panellists for each 
Delphi round. 
 
After the last round the project team discussed the results and made final decisions, taking 
into account the panellists’ additional comments. 
 
Ethical considerations 
Ethical approval was obtained by the Ethics review Committee (April 2016 – 
B670201628231). Return of a completed questionnaire was taken as consent to participate by 
the ISC and the panellists. All patients received written information about the theoretical 
purposes of the study and the way participation will strengthen clinical decision-making, 
contribute to patient-centered health care and improved IAD research. Oral and written 
informed consent was obtained from the participating patients. Participants’ information was 
treated anonymous and confidential.  
 
Data analysis 
Demographic data, as well as responses to the questionnaires, were described using frequency 
distributions. All statistical analyses were performed using SPSS statistical package version 
24 (SPSS, Inc., Chicago, IL, USA). 
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Validity and Reliability 
Several aspects supported the validity and reliability of the development process. The 
members of the project team and the ISC are all outstanding experts in the field of IAD. A 
protocol has been developed and published a priori (Van den Bussche et al. 2017). Two 
researchers (KV and DD) screened the literature and extracted the data and a third researcher 
(DB) was consulted in case of disagreement. The patient perspective was considered using 
interviews with patients and including all types of possible outcomes into the initial list. 
 
RESULTS 
Characteristics of the panellists 
A sample of 153 panellists (healthcare providers, researchers and industry) was invited to 
participate. Fifty-seven of the panellists (37.3%) participated in the first Delphi round, of 
which 43 (75.4%) participated in the second round and 37 (86.0%) participated also in the 
third round. A flowchart of the response rates of each round is presented in Figure S1 (see 
supplementary information). Socio-demographic characteristics, disciplines of expertise and 
experience of the panellists (presented per group and per round), can be found in Table S1 
(see supplementary information).  
 
List of potential core domains 
The systematic literature search resulted in 3826 records: 1407 in Web of Science, 1726 in 
PubMed, 489 in CINAHL and 204 in the Cochrane Library, of which 1190 duplicates were 
removed. Based on the screening of title and/or abstract, 2018 records were excluded. Based 
on the screening of the full texts, additional 384 records were excluded. In total, 234 records 
were relevant for outcome extraction. Hand searches identified ten additional relevant 
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articles. Outcomes were extracted from the final group of 244 articles. The results of the 
search and screening process are presented in Figure 2. Data extraction from the literature 
search resulted in 1852 outcomes, the consultation with the experts of the ISC resulted in 56 
outcome domains and the three patient interviews resulted in 32 outcome domains. The 
project team reviewed and refined the outcomes into outcome domains.  
 
The list of potential outcome domains generated by the project team and the ISC included 58 
outcome domains. Fifteen were classified into the core area ‘life impact’, three in ‘resource 
use/economic impact’ and 40 in ‘pathophysiological manifestations’. The list used at the start 
of the Delphi study is presented in Table S2 (see supplementary information). 
 
Delphi round 1 
The first round was performed between 7 April 7 – 7 May 2017. The results are presented in 
Table 1. Thirteen domains were considered critical for inclusion by at least 70% of the 
panellists from both groups. The remaining 45 domains did not reach this threshold and were 
not retained. Several panellists emphasized overlap between the outcome domains, possible 
problems regarding the potential capacity of patients to give feedback (e.g. due to cognitive 
or conscious state) and consequently to provide data for some of the outcome domains (e.g. 
‘self-reported symptoms’ and ‘pain’) and a potential for further detailed description of 
outcome domains. No additional outcome domains were collated. 
 
To address these concerns, a proposal was developed for the second round to: (1) merge the 
outcome domains ‘denudation’ and ‘skin loss’ with ‘erosion’ because of the similarities; (2) 
include ‘burden of care – patient perspective’ and ‘physical comfort’ in ‘IAD-related Quality 
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of Life’ because of overlap; (3) incorporate symptoms such as ‘burning’ and ‘stinging’ (as 
part of ‘self-reported symptoms’) in the definition of ‘pain’, resulting in the separate outcome 
‘itching’; (4) separate the ‘clinical signs of infection’ from the ‘clinical signs of 
inflammation’; and to (5) incorporate ‘erythema’ in ‘clinical signs of inflammation’ because 
of overlap.  
 
In total, nine outcome domains were presented to the panellists in the second round: ‘clinical 
signs of inflammation’, ‘clinical signs of infection’, ‘cost-effectiveness’, ‘erosion’, ‘IAD-
related Quality of Life’, ‘itching’, ‘maceration’, ‘pain’ and ‘patient satisfaction’. Appropriate 
definitions were searched for these domains and were presented in the second round for 
rating. 
 
Delphi round 2 
The second round was performed between 20 June – 4 July 2017. The results are presented in 
Table 2. Six domains met the a priori criteria for inclusion. The remaining domains ‘cost-
effectiveness’, ‘IAD-related Quality of Life’ and ‘itching’ did not reach the threshold. No 
additional outcome domains were collated. 
 
Based on the results and the comments of the panellists, it could be concluded that: (1) there 
was no agreement regarding definitions; (2) the number of ratings of ‘not important’ [1-3] 
was sometimes very high (even if ≥ 70% of panellists score ‘critical for inclusion’); and (3) 
there was overlap between some of the domains (e.g. ‘clinical signs of inflammation’ and 
‘pain’).  
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International Steering Committee consultation 
The results of the first and second Delphi round were presented to the ISC. The ISC was 
asked to give input on: (1) the results of the second Delphi round which indicated 
disagreement regarding the concepts; (2) the proposal to further summarize the concepts to 
key clinical signs/concepts to avoid overlap; (3) the definitions; and (4) the next potential 
steps. 
 
Based on the comments of the ISC, the decision was made to include ‘IAD-related Quality of 
Life’ and to change definitions. All members of the ISC agreed on organizing a third Delphi 
round. In total, seven outcome domains were presented to the panellists in the third round: 
‘erythema’, ‘erosion’, ‘maceration’, ‘IAD-related pain’, ‘major colonization and infection of 
IAD’, ‘IAD-related Quality of Life’ and ‘patient satisfaction’. 
 
Delphi round 3 
The third round was performed between August 28
 
to September 10, 2017. The ratings of the 
seven outcome domains are presented in Table 3. All outcome domains except ‘Major 
colonization and infection of IAD’ were approved by at least 70% of the panellists. Some 
fundamental concerns were raised by the panellists on both ‘major colonization and infection 
of IAD’ and ‘IAD-related Quality of Life’. 
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Final decisions 
Given the comments and voting behaviour of the panellists, the project team decided to omit 
the outcome domains ‘major colonization and infection of IAD’ and ‘IAD-related Quality of 
Life’. This does not imply that these outcome domains were not considered important or 
relevant, but that the results of the Delphi process did not allow them to be classified as 
‘critical’. Based on the results of the three-round Delphi study and consultation of the ISC, 
the project team agreed on the following final core set of five outcome domains as follows: 
‘erythema’, ‘erosion’, ‘maceration’, ‘IAD-related pain’ and ‘patient satisfaction’. 
 
DISCUSSION 
The purpose of this study was to develop a consensus-based core set of outcome domains to 
be applied in clinical research involving adults with IAD or at risk, independently from any 
geographical location or skin colour. The final COS for IAD in adults comprises five 
domains: ‘erythema’, ‘maceration’, ‘erosion’, ‘IAD-related pain’ and ‘patient satisfaction’.  
The outcome domains ‘erythema’, ‘maceration’ and ‘erosion’ are clinical signs and 
symptoms and reached the highest level of consensus in this study. They are critical elements 
of the clinical picture of IAD and are often included in IAD definitions (Gray et al. 2012, 
Mugita et al. 2015). Our results indicate that these signs are critical domains to be captured in 
all clinical studies in this area. 
 
‘IAD-related pain’ and ‘patient satisfaction’ reached a high level of consensus for inclusion 
in this core domain set. Both outcome domains comprise several components. Pain for this 
COS refers to the magnitude, the frequency and the quality of pain. ‘Patient satisfaction’ 
refers to the degree to which the individual regards the intervention or the procedure where it 
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is delivered as useful, effective, or beneficial. As indicated by the panellists, it is important 
for the choice of instruments to consider the capacity of patients to provide feedback (e.g. due 
to cognitive or conscious state). However, it will not always be possible to provide data for 
some of these outcome domains (Patrick et al. 2008). Several patient symptoms such as pain 
and burning, are included in several IAD assessment instruments, but no data were found for 
the domain ‘pain due to IAD’ in the (quasi-)RCTs included in a recent Cochrane review on 
interventions related to IAD prevention and treatment (Beeckman et al. 2016). 
 
From a COS perspective, the five identified domains are proposed as core concepts for ‘what’ 
to measure as outcomes in clinical IAD trials. The current results do not provide evidence 
‘how’ best to measure the five identified domains. This will be subject to future research. 
 
The following outcome domains were considered important but not critical for inclusion and 
were therefore omitted: ‘cost-effectiveness’, ‘IAD-related Quality of Life’ and ‘major 
colonization and infection’. ‘Cost-effectiveness’ was excluded from the COS since not 
reaching the 70% threshold in the third and final Delphi round.  
 
Although OMERACT recommends the inclusion in a COS of at least one outcome reflecting 
each core area, such as ‘resource use/economic impact’, empirical evidence is emerging that 
this is not always considered appropriate (Chiarotto et al. 2015, Williamson et al. 2017). 
Currently, little is known about the economic impact of IAD (Gray et al. 2007). 
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The outcome domain ‘major colonization and infection’ proved to be important throughout 
the entire Delphi process but no agreement regarding the description of that domain was 
obtained. Several panellists remarked that ‘clinical signs of infection’ are not necessarily 
always associated with IAD and therefore not critical. The signs in the definition were 
considered too general to allow an accurate diagnosis at the bedside. Since it is difficult to 
diagnose wound infection based on clinical observation, a (semi-)quantitative swab or other 
diagnostic tests should be considered (Cefalu et al. 2017, Institute 2016). However, this 
technique is time-consuming, expensive and often highly false-positive (Bowler et al. 2001). 
‘IAD-related Quality of Life’ incorporated ‘burden of care – patient perspective’ and 
‘physical comfort’ after the first Delphi round. Although considered important throughout the 
Delphi process, several panellists underlined that ‘Quality of Life’ could be highly influenced 
by other factors unrelated to an intervention, such as co-morbid conditions, the inability of 
some patient groups to rate this outcome and the lack of current measurement instruments.  
 
Our results do not mean that the excluded outcome domains are not important or relevant in 
clinical IAD trials. However, a COS represents a minimum number of critical outcomes to be 
measured and reported in all trials in a specific area. Trialists can select additional outcomes 
if deemed relevant (Schmitt et al. 2014).  
 
Strengths and limitations 
This is the first study conducted to obtain international and multidisciplinary consensus on 
core outcome domains to be reported in IAD clinical trials. Guided by the initiatives like 
COMET, OMERACT and the HOME roadmap endorsed by CSG-COUSIN, a literature 
review, expert and patient consultation and an international, multidisciplinary Delphi 
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procedure were conducted (Boers et al. 2014b, Schmitt et al. 2014, Williamson et al. 2017). 
A study protocol was published a priori and the COS-STAR statement was used to ensure a 
high standard of reporting (Kirkham et al. 2016, Van den Bussche et al. 2017). Another 
strength is the comprehensive list of outcomes initially obtained through an extensive search 
strategy, patient and expert interviews. This study also included opinions of several 
stakeholder groups (healthcare providers, researchers, industry) from around the international 
arena. Europe was represented most frequently (64.9% of panellists from 11 countries), 
followed by USA (22.8% of panellists from two countries). The input of different 
stakeholders from different cultures increases the generalizability and applicability of this 
COS (Boers et al. 2014a).  
 
This study had several limitations. The search for patients was difficult due to the acute 
nature of the condition in often care-dependent elderly and ICU patients. The inclusion of 
only three patients may limit the patients’ perspective on the search for outcomes. Patients 
were interviewed to contribute to the COS development, but they were not included in the 
subsequent Delphi rounds. Although patient views were considered, they were not included 
as research partners (Gargon et al. 2017). This could have influenced the prioritization of the 
outcome domains and the exclusion of ‘IAD-related Quality of Life’. However, this outcome 
domain was not mentioned by the patients during the interviews.  
 
Methodological guidance for COS development is available but several details are unclear 
(Sinha et al. 2011, Williamson et al. 2017, Williamson et al. 2012b). For instance, there is no 
reference standard for data extraction such as the level of abstraction. Since the independent 
data extraction by two reviewers was not performed, it is possible that some outcome 
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domains were not identified. There is also no reference standard for conducting Delphi 
methods and for consensus definitions (Brookes et al. 2016, Diamond et al. 2014). Currently, 
the nine-point scale is most often used in COS studies to measure agreement between Delphi 
study participants. The decision rules, often based on cut-offs, during the Delphi rounds are 
currently being questioned (Kottner et al. 2017). The use of strict thresholds to decide 
whether COS domains are kept or left out are considered arbitrary (Thorlacius et al. 2017). 
The usefulness of this procedure can be questioned as it is recommended to use the full range 
of information from rating scales otherwise they are not needed in that specific format 
(Beckstead 2014, Streiner et al. 2015). Driven by this methodological uncertainty, we decided 
to use two different scoring systems (a three-point and a nine-point scale) in the first Delphi 
to allow methodological reflection. This was a deviation from the protocol. 
 
Given the extent of the long list of 58 outcome domains, the project team decided to present 
only the outcome domains with 70% agreement (category ‘critical for inclusion’) instead of 
re-scoring all outcome domains that did not reach that threshold. For the same reason, only 
feedback on the general findings was provided. Although we included panellists from around 
the international arena, responses were not distributed equally [Asia (1.8%), Australia (7%) 
and Africa (3.5%)]. The decision not to include a consensus meeting in the COS development 
was a pragmatic one. Although several COS development studies hold a final consensus 
meeting, evidence on the design and results of a face-to-face meeting is lacking (Williamson 
et al. 2017).  
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CONCLUSION 
The COS for IAD in adults consists of the following outcome domains: ‘erythema’, 
‘maceration’, ‘erosion’, ‘IAD-related pain’ and ‘patient satisfaction’. It is recommended that 
all trials and non-randomised studies in this area should use these domains with the aim of 
improving transparency and to enhance comparability. Therefore, we recommend researchers 
to use this COS when preparing a new clinical trial. The next step will be to develop a core 
set of measurement instruments to be used to measure these outcome domains in adults with 
IAD or at risk, independently from any geographical location or skin colour. The selection of 
instruments will focus on those that have demonstrated adequate measurement properties for 
these domains with the least applicant and participant burden. 
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Core Outcome Set in IAD Research (CONSIDER): international and multidisciplinary consensus on a core 
set of outcome domains in incontinence-associated dermatitis research 
Table 1. Ratings of 58 outcome domains in the first Delphi round – 57 panellists 
Core Area and Domain 
Group 1
†
 
n = 28 
Group 2
‡
 
n = 29 
Result
¶
 
N (%) Not important Important Critical 
Don’t 
know
§
 
Not important Important Critical 
Don’t 
know
§
 
in or out 
Life Impact          
Burden of care from caregiver's perspective 1 (3.8) 13 (50.0) 12 (46.2) 2 2 (6.8) 4 (13.7) 23 (79.3) 0 Out 
Burden of care from patient perspective 0 (0) 4 (14.8) 23 (85.2) 1 2 (7.4) 1 (3.7) 24 (88.8) 0 In 
Health-related Quality of Life 2 (7.1) 7 (25.0) 19 (67.9) 0 3 (10.3) 1 (3.4) 25 (86.2) 0 Out 
Independence (IAD related) 3 (11.1) 11 (40.7) 13 (48.1) 1 1 (3.7) 7 (25.9) 19 (70.3) 2 Out 
Pain 0 (0) 4 (14.8) 23 (85.2) 1 1 (3.4) 0 (0) 28 (96.6) 0 In 
Physical comfort 0 (0) 7 (25.0) 21 (75.0) 0 2 (7.1) 3 (10.7) 23 (82,2) 1 In 
Physical functioning 4 (14.3) 8 (28.6) 16 (57.1) 0 3 (10.8) 8 (28.5) 17 (60.7) 1 Out 
Physical well-being 3 (11.5) 9 (34.6) 14 (53.8) 2 3 (10.2) 10 (34.4) 16 (55.1) 0 Out 
Psychological impact of the disease 2 (7.1) 9 (32.1) 17 (60.7) 0 2 (6.9) 8 (27.6) 19 (65.5) 0 Out 
Quality of Life (general) 5 (17.9) 10 (35.7) 13 (46.4) 0 4 (13.8) 9 (31) 14 (48.3) 2 Out 
Quality of Life (IAD related) 3 (11.1) 3 (11.1) 21 (77.8) 1 1 (3.6) 2 (7.2) 25 (89.3) 1 In 
Satisfaction with intervention from by caregiver's 
perspective 
3 (11.1) 12 (44.4) 12 (44.4) 1 3 (10.8) 3 (10.8) 22 (78.6) 1 Out 
Satisfaction with intervention from patient 
perspective 
1 (3.7) 7 (25.9) 19 (70.4) 1 2 (7.2) 1 (3.6) 25 (89.2) 1 In 
Self-reported symptoms 1 (3.6) 6 (21.4) 21 (75.0) 0 0 (0) 1 (6.8) 27 (93.1) 0 In 
Sleep (IAD related) 4 (14.3) 13 (46.4) 11 (39.3) 0 3 (10.8) 7 (25) 18 (64.3) 1 Out 
Resource use /economical impact          
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Caregivers' work productivity 4 (16.0) 13 (52.0) 8 (32.0) 2 4 (14.3) 8 (32.2) 15 (53.5) 1 Out 
Cost-effectiveness 0 (0.0) 19 (29.6) 27 (70.4) 1 2 (7.4) 4 (14.8) 21 (77.8) 2 In 
Costs  2 (7.4) 9 (33.3) 16 (59.3) 1 3 (10.3) 7 (24.1) 19 (65.4) 0 Out 
Pathophysiological manifestations          
Bleeding 6 (24.0) 7 (28.0) 12 (48.0) 1 4 (14.8) 5 (18.5) 18 (66.6) 1 Out 
Bullae 5 (20.0) 7 (28.0) 13 (52.0) 1 2 (8.4) 5 (20.8) 17 (70.8) 4 Out 
Clinical characteristics of skin surrounding IAD 
area assessed by caregiver 
1 (3.8) 8 (30.8) 17 (65.4) 2 1 (4.0) 5 (20.0) 19 (76) 3 Out 
Clinical signs of inflammation / colonisation / 
infection of IAD area assessed by caregiver 
0 (0.0) 6 (23.1) 20 (76.9) 2 2 (7.6) 2 (11.5) 21 (80.8) 2 In 
Cracking 5 (19.2) 12 (43.2) 9 (34.6) 2 3 (12.0) 5 (20.0) 17 (68.0) 3 Out 
Crusting 7 (26.9) 10 (38.5) 9 (34.6) 2 4 (15.4) 6 (16.0) 16 (61.5) 2 Out 
Denudation 2 (8.0) 4 (16.0) 19 (76.0) 1 2 (7.6) 1 (3.8) 23 (88.4) 2 In 
Desquamation 6 (24.0) 8 (32.0) 11 (44.0) 2 4 (15.3) 2 (7.7) 17 (65.4) 2 Out 
Discolouration 5 (19.2) 7 (26.9) 14 (53.8) 0 2 (8.4) 5 (20.9 17 (70.8) 4 Out 
Dryness 5 (19.2) 11 (42.3) 10 (38.5) 0 4 (16.0) 5 (20.0) 16 (64.0) 3 Out 
Erosion 1 (4.0) 6 (24.0) 18 (72.0) 1 4 (16.0) 2 (8.0) 19 (76.0) 3 In 
Erythema 1 (3.8) 3 (11.5) 22 (84.6) 0 1 (4.0) 2 (8.0) 22 (88.0) 3 In 
Excoriation 5 (20.8) 7 (29.2) 12 (50.0) 2 5 (20.0) 6 (24.0) 14 (56.0) 3 Out 
Exudate 4 (15.4) 7 (26.9) 15 (57.7) 0 2 (7.6) 5 (19.2) 19 (73.1) 2 Out 
Glossy/shiny appearance 5 (19.2) 10 (38.5) 11 (42.3) 0 2 (6.8) 4 (13.7) 20 (68.9) 2 Out 
Infection confirmed by culture  4 (16.0) 7 (28.0) 14 (56.0) 1 5 (19.1) 5 (19.2) 16 (61.6) 2 Out 
Lichenification 9 (40.9) 11 (50.0) 2 (9.1) 4 7 (26.9) 8 (30.7) 11 (42.3) 2 Out 
Maceration 1 (3.8) 4 (15.4) 21 (80.8) 0 1 (3.8) 4 (15.4) 21 (80.8) 2 In 
Macules 7 (33.3) 10 (47.6) 4 (19.0) 4 5 (20.0) 9 (36.0) 11 (44.0) 3 Out 
Maculopapular rash 4 (18.2) 10 (45.5) 8 (36.4) 4 3 (12.5) 6 (25.0) 15 (62.5) 4 Out 
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Necrosis 9 (37.5) 7 (29.2) 8 (33.3) 2 6 (25) 6 (25) 12 (49.9) 4 Out 
Nodules 10 (43.5) 12 (52.2) 1 (4.3) 3 12 (50.0) 8 (33.3) 4 (16.7) 4 Out 
Oedema 5 (19.2) 13 (50.0) 8 (30.8) 0 4 (16.0) 5 (20.0) 16.0 (64.0) 3 Out 
Oozing 7 (29.2) 11 (45.8) 6 (25.0) 2 5 (21.7) 5 (21.7) 13 (56.4) 5 Out 
Papules 10 (41.7) 10 (41.7) 4 (16.7) 2 5 (20.0) 4 (16.0) 16 (64.0) 3 Out 
Pigmentation 10 (38.5) 13 (50.0) 3 (11.5) 0 3 (12.5) 11 (45.8) 10 (41.7) 4 Out 
Purulent exudate 9 (34.6) 8 (30.8) 9 (34.6) 0 5 (20.0) 8 (32.0) 12 (48.0) 3 Out 
Pustules 10 (38.5) 6 (23.1) 10 (38.5) 0 3 (12.0) 3 (12.0) 19 (76.0) 3 Out 
Roughness 12 (48.0) 11 (44.0) 2 (8.0) 1 9 (36.0) 9 (36.0) 7 (28.0) 3 Out 
Satellite lesions 2 (7.7) 8 (30.8) 16 (61.5) 0 1 (3.8) 3 (11.4) 22 (84.6) 2 Out 
Scabbing 10 (40.0) 12 (48.0) 3 (12.0) 1 4 (16.7) 9 (37.5) 11 (45.8) 4 Out 
Scaling 10 (40.0) 10 (40.0) 5 (20.0) 1 4 (16.0) 9 (44.0) 12 (48.0) 3 Out 
Scratch marks 10 (38.5) 12 (46.2) 4 (15.4) 0 7 (26.9) 11 (42.2) 8 (30.7) 2 Out 
Shiny appearance 6 (23.1) 12 (46.2) 8 (30.8) 0 4 (15.3) 6 (23.1) 16 (61.5) 2 Out 
Skin barrier properties 4 (16.0) 8 (32.0) 13 (52.0) 1 4 (16.7) 1 (4.2) 19 (79.1) 4 Out 
Skin loss 1 (3.8) 4 (15.4) 21 (80.8) 0 1 (4.0) 2 (8.0) 22 (88.0) 3 In 
Slough present in the wound bed (yellow / brown 
/ greyish) 
7 (26.9) 11 (42.3) 8 (30.8) 0 5 (19.2) 6 (23.0) 15 (57.7) 2 Out 
Swelling 7 (26.9) 9 (34.6) 10 (38.5) 0 5 (20.3) 6 (25.0) 13 (54.2) 4 Out 
Vesicles 4 (16.0) 10 (40.0) 11 (44.0) 1 4 (16.0) 5 (20.0) 16 (64.0) 3 Out 
White scaling 7 (33.3) 12 (571) 2 (9.5) 5 10 (45.4) 3 (13.6) 9 (41.9) 6 Out 
IAD, incontinence-associated dermatitis. † 3-point scale [(1) not important enough to be considered in the COS for IAD, (2) important but not critical to be considered in the COS for IAD, and (3) critical, 
should be included in the COS for IAD]. ‡ 9-point scale [from ‘not important for inclusion’ to ‘critical, should be included in a COS for IAD’]. § Don’t know: ‘I can’t rate the importance of the outcome 
because I don’t know the outcome’. ¶ 70% of panelists in both groups rate the outcome as ‘critical for inclusion’. 
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Core Outcome Set in IAD Research (CONSIDER): international and 
multidisciplinary consensus on a core set of outcome domains in 
incontinence-associated dermatitis research 
 
Table 2. Ratings of 9 outcome domains in the second Delphi round – 43 panellists 
Outcome domain and definition n (%) 
Not 
important
†
 
Important Critical Result
‡
 
1. Clinical signs of inflammation 
Clinical signs of inflammation is defined as the presence of dolor 
(pain), rubor (erythema), calor (warmth), tumor (edema/swelling), 
and function lesa (disturbed skin barrier) (Schultz et al., 2003). 
1 (2.3) 3 (7.0) 39 (90.8) In 
2. Clinical signs of infection 
Clinical signs of infection is defined as the presence of nonhealing, 
pain, increased wound size, warmth, white scaling of the skin 
(suggesting a fungal infection), satellite lesions (pustules 
surrounding the lesion, suggesting a Candida albicans fungal 
infection), slough visible in the wound bed (yellow/brown/greyish), 
a green appearance within the wound bed (suggesting a bacterial 
infection with Pseudomonas aeruginosa), increased exudate levels, 
purulent exudate (pus), or a shiny appearance of the wound bed due 
to the presence of replicating microorganisms within the wound and 
the presence of injury to the host (adapted from Schultz et al., 2003). 
3 (6.9) 3 (6.9) 37 (86.1) In 
3. Cost-effectiveness  
Cost-effectiveness is defined as the ratio of the cost of the 
intervention to the health effects of the intervention (Gold, 1996). 
2 (4.6) 14 (32.7) 27 (62.8) Out 
4. Erosion  
Erosion is defined as the loss of either a portion or the entire 
epidermis (Nast et al., 2015). 
1 (2.3) 3 (7.0) 39 (90.7) In 
5. IAD-related Quality of Life 
IAD-related Quality of Life is defined as physical, material, social, 
and emotional wellbeing and comfort compromised by the presence 
of IAD and its associated care by (in)formal caregivers (Felce and 
Perry, 1995).  
1 (2.3) 13 (30.3) 29 (67.5) Out 
6. Itching 
Itching is defined as the unpleasant cutaneous sensation which 
provokes the desire to scratch (Ständer et al., 2007). 
5 (11.7) 13 (30.3) 25 (58.2) Out 
7. Maceration 
Maceration is defined as the softening and subsequent breakdown 
of skin characterized by a whitened appearance and swelling caused 
by prolonged exposure to moisture (Ichikawa-Shigeta et al. 2014; 
Mugita et al., 2015). 
3 (7.0) 3 (6.9) 37 (86.1) In 
8. Pain 
Pain is defined as the magnitude and frequency of how much a 
patient hurts at the affected area. Pain can be expressed by the 
0 (0.0) 5 (11.7) 38 (88.4) In 
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patient as stinging, tingling of burning. 
9. Patient satisfaction 
Patient satisfaction is defined as the degree to which the individual 
regards the health care service or product (the intervention) or the 
manner in which it is delivered by the provider as useful, effective, 
or beneficial (NCBI MeSH term definition). 
3 (7.0) 6 (13.9) 34 (79.1) In 
IAD, incontinence-associated dermatitis. † 9-point scale [from ‘not important for inclusion’ to ‘critical, should be included in a 
COS for IAD’]. ‡ 70% of panelists rate the outcome as ‘critical for inclusion’. 
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Table 3. Ratings of 7 outcome domains in the third Delphi round – 37 panellists 
Outcome domain and definition n(%) 
Yes, I 
approve 
Yes, I approve 
but with minor 
suggestions 
No, I have 
major 
concerns 
Result 
1. Erythema 
Erythema is defined as redness of the skin. A variety of tones of 
redness may be present. In patients with darker skin tones, the 
skin may be paler or darker than their normal skin colour, or 
purple. 
34 (91.9) 3 (8.1) 0 (0.0) In 
2. Erosion  
Erosion is defined as the loss of either a portion or either the 
entire epidermis (Nast et al., 2015). 
32 (86.5) 5 (13.5) 0 (0.0) In 
3. Maceration  
Maceration of the skin is defined as the softening of the 
epidermis and dermis characterized by a whitened appearance 
and swelling caused by prolonged exposure to urine and feces 
(Ichikawa-Shigeta et al. 2014; Mugita et al., 2015). 
27 (73.0) 9 (24.3) 1 (2.7) In 
4. IAD related pain  
IAD related pain is defined as a symptom that is subjectively 
expressed by the patient. It composes of both the magnitude and 
the frequency of how much at the affected area hurts. Pain can 
be expressed as non-verbal sounds (e.g. crying), vocal 
complaints of pain (e.g. that hurts), facial expressions (e.g. 
grimaces), protective body movements or postures (e.g. bracing). 
29 (78.4) 8 (21.6) 0 (0.0) In 
5. Major colonization and infection of IAD 
Major colonization and infection of IAD can manifest both 
loco-regional and/or systemically: 
 Loco-regional signs of major colonization of IAD are 
(increased) malodor, increased wound size, increased exudate 
levels, purulent exudate (pus), slough visible in the wound bed 
(yellow/brown/greyish/green), and shiny appearance of the 
wound bed (friable granulation tissue). 
 Loco-regional signs of microbiological infection of 
IAD are rubor (redness), calor (increased localized warmth), 
dolor (increased and excessive level pain), and tumor (increased 
edema/swelling). 
 Loco-regional signs of bacterial infection of IAD 
include (increased) malodor, increased wound size, increased 
exudate levels, purulent exudate (pus), slough visible in the 
wound bed (yellow/brown/greyish/green), and shiny appearance 
of the wound bed (friable granulation tissue). 
 Loco-regional signs of fungal infection of IAD are 
white scaling on the edge of the lesion, and satellite lesions 
(pustules surrounding the lesion). 
 Signs of systemic infection related to the presence of 
20 (54.1) 11 (29.7) 6 (16.2) Out 
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IAD may include fever, malaise, tachycardia, and hypotension. 
6. IAD related Quality of Life  
IAD related Quality of Life is defined as the degree of 
physical, material, social, and emotional wellbeing and comfort 
compromised by the presence of IAD and its associated care by 
(in)formal caregivers (Felce and Perry, 1995).  
30 (81.1) 3 (8.1) 4 (10.8) Out 
7. Patient satisfaction  
Patient satisfaction is defined as the degree to which the 
individual regards the intervention (e.g. service, product, 
program) or the procedure in which it is delivered as useful, 
effective, or beneficial (based on NCBI MeSH term definition). 
33 (89.2) 3 (8.1) 1 (2.7) In 
IAD, incontinence-associated dermatitis. 
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Core Outcome Set in IAD Research (CONSIDER): international and 
multidisciplinary consensus on a core set of outcome domains in 
incontinence-associated dermatitis research 
Identification of outcomes (n 
= 1852) used in previous 
studies via literature review
Generation of outcomes list
Outcomes (n = 56) retrieved 
from the International 
Steering Committee (ISC) 
Outcomes (n = 32) retrieved 
from 3 interviews with 
patients
Classification of outcomes into domains by project team (PT) and ISC. 
List of outcomes (n = 58)
PT and ISC review of outcomes list
Scoring of 58 outcomes using 2 scoring systems by 57 panelists (including ISC)
 Group A: 9-point scale [not important – critical]
 Group B: 3-point scale [(1) not important, (2) important but not critical, (3) critical]
Results are shown per group (Table 1).
Delphi Round 1
Scoring of 9 outcomes using the 9-point scale by 43 panelists (including ISC)
Results of all panelists are shown (Table 2).
Delphi Round 2
ISC was consulted and the decision was made to
 include IAD-related Quality of Life
 exclude cost-effectiveness, itching and clinical signs of inflammation 
 organize a third Delphi round
ISC review
Scoring of 7 outcomes using a 3-point scale [(1) Yes, I approve, (2) Yes, I approve but with 
minor suggestions, (3) No, I have major concerns] by 37 panelists (including ISC)
Results of all panelists are shown (Table 3).
Delphi Round 3
Final Core Outcome Set
 Clinical signs: erythema, maceration and erosion
 IAD-related pain
 Patient satisfaction
 
Figure 1. COS domain development process 
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Articles identified from 
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n = 3826
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Number of outcomes 
retrieved from experts of the 
International Steering 
Committee
n = 56
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Total articles identified
n = 2636
Articles excluded because of duplicate
n = 1190 
Articles excluded based on title/abstract
 Pediatric n = 706
 Language n = 2
 Scope n = 1310
Articles excluded based on full text
 Pediatric n = 248
 Language n = 11
 Scope n = 77
 No full text n = 48
Articles included 
n = 244
Additional articles from 
reference lists
n = 10
Number of outcomes 
retrieved from literature
n = 1852
Number of outcomes 
retrieved from patients
n = 32
 
Figure 2. Results of search strategy and outcome extraction 
 
 
